| Cat.No. | Name | Information |
|---|---|---|
| M1766 | PF-04217903 | PF-04217903 (PF-4217903) is a novel ATP-competitive small molecule inhibitor of c-Met kinases with the IC50 values from 3.1 nM to142 nM. |
| M2080 | Capmatinib (INCB28060) | Capmatinib (INCB28060) is a novel inhibitor of c-MET kinase with IC50 of 0.13 nM. |
| M1765 | Crizotinib (PF-02341066) | Crizotinib (PF-02341066) is a potent, orally bioavailable, ATP-competitive small-molecule inhibitor of c-Met kinase and ALK (anaplastic lymphoma kinase) with IC50 values to be 4 and 25 nM for C-Met and ALK resepectively. |
| M1757 | XL-184 | XL184 is a small molecule inhibits multiple receptor tyrosine kinases, specifically MET and VEGFR2 with IC50 values of 0.035 and 1.8 nM for VEGFR2 and Met respectively. |
| M43488 | Canlitinib | Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). |
| M43487 | Norleual TFA | Norleual TFA, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. |
| M43486 | Tyrosine kinase-IN-6 | Tyrosine kinase-IN-6 is a potent and promising RON splice variants inhibitor with anti-cancer and o?antineoplastic effects. |
| M40734 | Tepotinib Hydrochloride Hydrate | Tepotinib Hydrochloride Hydrate is a potent, selective c-Met inhibitor with an IC50 of 4 nM and is more than 200-fold more selective for c-Met than for IRAK4, TrkA, Axl, IRAK1 and Mer. |
| M40733 | Capmatinib hydrochloride | Capmatinib hydrochloride is a potent, orally active, selective, ATP-competitive c-Met kinase inhibitor that inhibits the phosphorylation of c-MET and downstream effector proteins of the c-MET pathway, with an IC50 value of 0.13 nM. In addition, Capmatinib hydrochloride In addition, Capmatinib hydrochloride can inhibit the proliferation and migration of c-Met-dependent tumor cells, and can effectively induce apoptosis (apoptosis), with anti-tumor activity. |
| M30821 | MET kinase-IN-4 | MET kinase-IN-4 is an orally active Met kinase inhibitor. MET kinase-IN-4 has potent Met kinase inhibitory activity with an IC50 value of 1.9 nM. MET kinase-IN-4 can be used for the research of cancer. |
| M29825 | Boditrectinib oxalate | Boditrectinib oxalate is a potent tyrosine kinase inhibitor. Boditrectinib oxalate serves as an antineoplastic agent. Boditrectinib oxalate is useful in the research of cancer, inflammation, neurodegenerative diseases and certain infectious diseases. |
| M29591 | Adrixetinib | Adrixetinib is an inhibitor of protein tyrosine kinase with antineoplastic activity. |
| M29374 | Emzeltrectinib | Emzeltrectinib is a potent tyrosine kinase inhibitor with antineoplastic activity. |
| M29079 | Mefatinib | Mefatinib is a potent tyrosine kinase inhibitor with antineoplastic activity. |
| M29036 | Boditrectinib | Boditrectinib is a potent tyrosine kinase inhibitor. Boditrectinib serves as an antineoplastic agent. Boditrectinib is useful in the research of cancer, inflammation, neurodegenerative diseases and certain infectious diseases. |
| M28938 | SRI 31215 TFA | SRI 31215 (TFA) is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer. |
| M28751 | Mefatinib free base | Mefatinib free base is a potent tyrosine kinase inhibitor with antineoplastic activity. |
| M28116 | MK-8033 hydrochloride | MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs). |
| M27745 | Terevalefim | Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor. |
| M27653 | Tyrosine kinase inhibitor | Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor. |
| M27598 | MK-8033 | MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs). |
| M25260 | Rilotumumab | Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. |
| M24631 | Emibetuzumab | Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer. |
| M24554 | Onartuzumab | Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
